These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6168830)

  • 1. Clinical pharmacokinetics of intravenous and oral bretylium tosylate in survivors of ventricular tachycardia or fibrillation: clinical application of a new assay for bretylium.
    Anderson JL; Patterson E; Wagner JG; Johnson TA; Lucchesi BR; Pitt B
    J Cardiovasc Pharmacol; 1981; 3(3):485-99. PubMed ID: 6168830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and intravenous bretylium disposition.
    Anderson JL; Patterson E; Wagner JG; Stewart JR; Behm HL; Lucchesi BR
    Clin Pharmacol Ther; 1980 Oct; 28(4):468-78. PubMed ID: 7408407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of bretylium in man after intravenous administration.
    Narang PK; Adir J; Josselson J; Yacobi A; Sadler J
    J Pharmacokinet Biopharm; 1980 Aug; 8(4):363-72. PubMed ID: 7431227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.
    Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1979 Aug; 91(2):229-38. PubMed ID: 380436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bretylium tosylate: a review.
    Bryan CK; Darby MH
    Am J Hosp Pharm; 1979 Sep; 36(9):1189-92. PubMed ID: 386786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of [14C]bretylium tosylate in rats.
    Kamath BL; Stampfli HF; Lai CM; Yacobi A
    J Pharm Sci; 1981 Jun; 70(6):667-9. PubMed ID: 7252812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of refractory ventricular tachycardia and fibrillation by bretylium tosylate: a report of 4 cases].
    Li SZ; Xu XH
    Zhonghua Xin Xue Guan Bing Za Zhi; 1987 Aug; 15(4):203-4, 12. PubMed ID: 3440418
    [No Abstract]   [Full Text] [Related]  

  • 9. Massive intravenous bolus bretylium tosylate.
    Bodnar T; Nowak R; Tomlanovich MC
    Ann Emerg Med; 1980 Dec; 9(12):630-3. PubMed ID: 7447102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy. Report of two cases.
    Anderson JL; Popat KD; Pitt B
    Arch Intern Med; 1981 May; 141(6):801-2. PubMed ID: 7235792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate.
    Patterson E; Gibson JK
    Circulation; 1981 Nov; 64(5):1045-50. PubMed ID: 7285294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of bretylium to suppress inducible ventricular tachycardia.
    Greene HL; Werner JA; Gross BW; Sears GK
    Am Heart J; 1983 May; 105(5):717-21. PubMed ID: 6846114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bretylium tosylate in the management of recurrent ventricular fibrillation complicating acute myocardial infarction.
    Dhurandhar RW; Pickron J; Goldman AM
    Heart Lung; 1980; 9(2):265-70. PubMed ID: 6898604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic testing of bretylium tosylate in sustained ventricular tachycardia.
    Bauernfeind RA; Hoff JV; Swiryn S; Palileo E; Strasberg B; Scagliotti D; Rosen KM
    Am Heart J; 1983 Jun; 105(6):973-80. PubMed ID: 6858846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination.
    Kamath BL; Gibson TP; Look ZM; McEntegart CM; Comrie EB; Yacobi A
    J Pharm Sci; 1982 Nov; 71(11):1294-6. PubMed ID: 7175729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration.
    Garrett ER; Green JR; Bialer M
    Biopharm Drug Dispos; 1982; 3(2):129-64. PubMed ID: 7104462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution of [14C]bretylium tosylate in rats.
    Yacobi A; Kamath BL; Lai CM; Stampfli HF
    J Pharm Sci; 1983 May; 72(5):556-9. PubMed ID: 6864505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of bretylium in prehospital ventricular fibrillation.
    Harrison EE; Amey BD
    Am J Emerg Med; 1983 Jul; 1(1):1-6. PubMed ID: 6680596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram for bretylium dosing in renal impairment.
    Adir J; Narang PK; Josselson J
    Ther Drug Monit; 1985; 7(3):265-8. PubMed ID: 4049461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
    Kowey PR; Levine JH; Herre JM; Pacifico A; Lindsay BD; Plumb VJ; Janosik DL; Kopelman HA; Scheinman MM
    Circulation; 1995 Dec; 92(11):3255-63. PubMed ID: 7586312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.